Novavax to Participate in Jefferies London Healthcare Conference

Rhea-AI Summary

Novavax (NVAX) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company will engage in a fireside chat on November 20, 2024, from 11:00 to 11:25 AM GMT in London. The session will be moderated by Roger Song, MD, CFA, with participation from President and CEO John C. Jacobs and other management team members.

The company will also conduct investor meetings on the same day. A replay of the fireside chat will be accessible for 30 days on Novavax's investor relations website at ir.novavax.com.

GAITHERSBURG, Md., Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.

Conference Details:
Fireside Chat
Date:	Wednesday, November 20, 2024
Time:	11:00 – 11:25 a.m. Greenwich Mean Time
Location:	London, United Kingdom
Moderator:	Roger Song, MD, CFA, Equity Analyst
Novavax participants:	John C. Jacobs, President and Chief Executive Officer and Additional Management Team Members
Investor Meetings
Date:	Wednesday, November 20, 2024

Recordings
A replay of the fireside chat will be available on the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. 

Contacts:     
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com  

Media
Giovanna Chandler
202-709-5563 
media@novavax.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-london-healthcare-conference-302303166.html

SOURCE Novavax, Inc.

FAQ

When is Novavax (NVAX) presenting at the Jefferies London Healthcare Conference 2024?

Novavax is presenting at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, from 11:00 to 11:25 AM Greenwich Mean Time in London.

Who will represent Novavax (NVAX) at the Jefferies London Healthcare Conference 2024?

President and CEO John C. Jacobs, along with additional management team members, will represent Novavax at the conference.

How can I access the replay of Novavax's (NVAX) Jefferies Conference presentation?

A replay of the fireside chat will be available on Novavax's investor relations website (ir.novavax.com) for 30 days following the conference.

What type of session will Novavax (NVAX) participate in at the Jefferies Conference?

Novavax will participate in a fireside chat moderated by Roger Song, MD, CFA, Equity Analyst, and will also conduct investor meetings.